AnchorDx Medical Co., Ltd, a specialist in methylation high-throughput sequencing based in China, has entered into a partnership with DiaCarta, Ltd, a US-based precision molecular diagnostics company. The collaboration aims to focus on the development and commercialization of cancer screening products, leveraging their proprietary technologies in DNA methylation and mutation detection to create molecular diagnostic products for the global market and pursue rapid commercial transformation.
AnchorDx’s Achievements and Products
Founded in 2015 and headquartered in Guangzhou, AnchorDx boasts a flagship product, UriFind, a DNA methylation detection diagnostic product that received breakthrough therapy designation (BTD) in the US in July 2021. The company is currently conducting a prospective regulatory study to support the Premarket Approval (PMA) filing for UriFind in the US, with DiaCarta’s active involvement.
DiaCarta’s Contribution and Services
DiaCarta, on the other hand, offers a range of testing services, including QClamp qPCR detection and OptiSeq XNA-NGS panel. They are also known for their QuantiVirus SARS-CoV-2 product, which has received approvals in both the US and the European Union, highlighting their expertise in molecular diagnostics.
Joint Vision for Molecular Diagnostics
The partnership between AnchorDx and DiaCarta is poised to accelerate the development of innovative molecular diagnostic products that can significantly impact cancer screening and detection worldwide. By combining their strengths and proprietary technologies, the two companies aim to enhance the precision and accessibility of molecular diagnostics, ultimately improving patient outcomes.- Flcube.com
